Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trichosporonosis.

T J Walsh1

  • 1Section of Infectious Diseases, Pediatric Branch, National Cancer Institute, Bethesda, Maryland.

Infectious Disease Clinics of North America
|March 1, 1989
PubMed
Summary
This summary is machine-generated.

Disseminated trichosporonosis, a rare fungal infection caused by Trichosporon beigelii, affects immunocompromised individuals. This severe systemic mycosis often resists standard antifungal treatments and carries a high mortality rate.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunosuppressed Adult Zebrafish Model of Mucormycosis.

Antimicrobial agents and chemotherapy·2018
Same author

Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections.

Drugs of today (Barcelona, Spain : 1998)·2017
Same author

Antimicrobial peptides as potential new antifungals.

Mycoses·2017
Same author

Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.

Clinical pharmacology and therapeutics·2017
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Clinical pharmacology and therapeutics·2016
Same author

Entomophthoramycosis: a neglected tropical mycosis.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2016
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Area of Science:

  • Mycology
  • Infectious Diseases
  • Immunocompromised Host Research

Background:

  • Disseminated trichosporonosis is an uncommon fungal infection.
  • It is increasingly reported in immunocompromised patients.
  • Trichosporon beigelii is the causative agent.

Purpose of the Study:

  • To review the clinical presentation and outcomes of disseminated trichosporonosis.
  • To highlight the challenges in treating this infection.
  • To emphasize the high fatality rate associated with this mycosis.

Main Methods:

  • Literature review of reported cases.
  • Analysis of clinical manifestations including fungemia, cutaneous lesions, pulmonary infiltrates, and azotemia.
  • Evaluation of treatment responses to conventional antifungal therapy.

Related Experiment Videos

Main Results:

  • Disseminated trichosporonosis presents with diverse symptoms.
  • The infection is often refractory to standard antifungal treatments.
  • High mortality rates are observed in affected patients.

Conclusions:

  • Disseminated trichosporonosis is a severe, often fatal, systemic mycosis.
  • Effective treatment strategies remain a challenge.
  • Further research into novel therapies is warranted for immunocompromised patients.